Study for Participants Continuing from Pfizer-Sponsored Palbociclib Studies
Sponsor: Pfizer
ClinicalTrials ID:NCT05226871
This clinical trial is for participants who have been benefiting from a previous Pfizer-sponsored study involving the medicine Palbociclib. The study aims to continue providing the medicine and monitor its safety.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
The goal of this study is to continue providing the study medicine, Palbociclib, to participants who have been benefiting from it in a previous Pfizer-sponsored study. The study will monitor the safety of the medicine while participants continue their treatment. Participants must agree to follow certain guidelines related to reproduction and be willing to attend all scheduled visits and follow the treatment plan. They must also provide signed consent to participate.
Description
This study allows eligible participants to continue receiving Palbociclib treatment if they have been benefiting from it in a previous Pfizer-sponsored study. The study is open-label, meaning both the participants and researchers know what treatment is being given. Participants will continue their treatment as they did in the previous study, and their experiences will be monitored to ensure the medicine's safety. The study requires participants to follow specific guidelines and attend all scheduled visits and procedures.
Eligibility Criteria
Inclusion Criteria
- Participants who are currently receiving Palbociclib treatment and benefiting from it in a previous Pfizer-sponsored study.
- Must agree to follow guidelines related to reproduction.
- Willing and able to attend all scheduled visits and follow the treatment plan.
- Able to provide signed consent to participate in the study.
Exclusion Criteria
- Any medical condition that, according to the study doctor or sponsor, would prevent participation in the study.
Get This Program In Your Inbox
Receive detailed information about this treatment opportunity to review with your healthcare provider.